Lexeo Therapeutics (LXEO) Amortization of Deferred Charges (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Amortization of Deferred Charges of $393000.0 for Q1 2026, up 8.86% on a YoY basis from $361000.0 in Q1 2025, and up 2.08% sequentially from $385000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Amortization of Deferred Charges data on file, last reported at $393000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 8.86% year-over-year to $393000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 7.86% YoY), and the FY2025 full-year result was $1.5 million, up 8.59% from the prior year.
- Amortization of Deferred Charges grew to $393000.0 in Q1 2026, from $385000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $393000.0 in Q1 2026 to a low of $297000.0 in Q4 2022.
- A 5-year average of $344285.7 and a median of $342500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 14.19% in 2024, while the deepest fall reached 0.31% in 2024.
- Tracing LXEO's Amortization of Deferred Charges over 5 years: stood at $297000.0 in 2022, then advanced by 12.46% to $334000.0 in 2023, then grew by 9.58% to $366000.0 in 2024, then rose by 5.19% to $385000.0 in 2025, then climbed by 2.08% to $393000.0 in 2026.
- Business Quant data shows LXEO's Amortization of Deferred Charges at $393000.0 in Q1 2026, $385000.0 in Q4 2025, and $377000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn |
| 10 | Lexeo Therapeutics | 374.26 Mn | 374.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 393,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Dec 31, 2025 | 385,000.00 |
| Dec 31, 2025 | 385,000.00 |
| Sep 30, 2025 | 377,000.00 |
| Sep 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Sep 30, 2024 | 346,000.00 |
| Sep 30, 2024 | 346,000.00 |
| Jun 30, 2024 | 339,000.00 |
| Jun 30, 2024 | 339,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Dec 31, 2023 | 334,000.00 |
| Dec 31, 2023 | 334,000.00 |